The relative dose intensity of first-line FOLFOXIRI and FOLFOX/FOLFIRI both in combination with bevacizumab affects prognosis of metastatic colorectal cancer patients: A pooled analysis of TRIBE and TRIBE2 studies.

Saved in:
Bibliographic Details
Title: The relative dose intensity of first-line FOLFOXIRI and FOLFOX/FOLFIRI both in combination with bevacizumab affects prognosis of metastatic colorectal cancer patients: A pooled analysis of TRIBE and TRIBE2 studies.
Authors: Moretto R; Unit of Medical Oncology 2, Azienda Ospedaliera Universitaria Pisana, Pisa, Italy., Rossini D; Unit of Medical Oncology 2, Azienda Ospedaliera Universitaria Pisana, Pisa, Italy; Department of Translational Research and New Technologies in Medicine and Surgery, University of Pisa, Pisa, Italy; Department of Experimental and Clinical Medicine, University of Florence. Oncology Unit, Careggi University Hospital, Florence, Italy., Polito MG; Department of Medical Oncology, Campus Bio-Medico University, Rome, Italy., Antoniotti C; Unit of Medical Oncology 2, Azienda Ospedaliera Universitaria Pisana, Pisa, Italy; Department of Translational Research and New Technologies in Medicine and Surgery, University of Pisa, Pisa, Italy., Intini R; Oncology 1 Unit Department of Oncology, Veneto Institute of Oncology IOV-IRCCS, Padua, Italy., Conca V; Unit of Medical Oncology 2, Azienda Ospedaliera Universitaria Pisana, Pisa, Italy; Department of Translational Research and New Technologies in Medicine and Surgery, University of Pisa, Pisa, Italy., Andena P; Medical Oncology Department, Fondazione IRCCS Istituto Nazionale dei Tumori, Milan, Italy., Carullo M; Unit of Medical Oncology 2, Azienda Ospedaliera Universitaria Pisana, Pisa, Italy; Department of Translational Research and New Technologies in Medicine and Surgery, University of Pisa, Pisa, Italy., Salvatore L; Medical Oncology Comprehensive Cancer Center, Fondazione Policlinico Universitario Agostino Gemelli, IRCCS, Rome, Italy; Medical Oncology, Università Cattolica del Sacro Cuore, Rome, Italy., Germani MM; Department of Translational Research and New Technologies in Medicine and Surgery, University of Pisa, Pisa, Italy., Bergamo F; Oncology 1 Unit Department of Oncology, Veneto Institute of Oncology IOV-IRCCS, Padua, Italy., Passardi A; Department of Medical Oncology, IRCCS Istituto Romagnolo per lo Studio dei Tumori (IRST) Dino Amadori, Meldola, Italy., Ciracì P; Unit of Medical Oncology 2, Azienda Ospedaliera Universitaria Pisana, Pisa, Italy; Department of Translational Research and New Technologies in Medicine and Surgery, University of Pisa, Pisa, Italy., Tamburini E; Department of Oncology and Palliative Care, Cardinale G Panico, Tricase City Hospital, Tricase, Italy., Boccaccio C; Unit of Medical Oncology 2, Azienda Ospedaliera Universitaria Pisana, Pisa, Italy; Department of Translational Research and New Technologies in Medicine and Surgery, University of Pisa, Pisa, Italy., Zaniboni A; Oncology Unit, Fondazione Poliambulanza, Brescia, Italy., Masi G; Unit of Medical Oncology 2, Azienda Ospedaliera Universitaria Pisana, Pisa, Italy; Department of Translational Research and New Technologies in Medicine and Surgery, University of Pisa, Pisa, Italy., Pietrantonio F; Medical Oncology Department, Fondazione IRCCS Istituto Nazionale dei Tumori, Milan, Italy., Lonardi S; Oncology 1 Unit Department of Oncology, Veneto Institute of Oncology IOV-IRCCS, Padua, Italy., Cremolini C; Unit of Medical Oncology 2, Azienda Ospedaliera Universitaria Pisana, Pisa, Italy; Department of Translational Research and New Technologies in Medicine and Surgery, University of Pisa, Pisa, Italy. Electronic address: chiaracremolini@gmail.com.
Source: European journal of cancer (Oxford, England : 1990) [Eur J Cancer] 2025 Jun 03; Vol. 222, pp. 115470. Date of Electronic Publication: 2025 Apr 26.
Publication Type: Journal Article; Clinical Trial, Phase III
Journal Info: Publisher: Elsevier Science Ltd Country of Publication: England NLM ID: 9005373 Publication Model: Print-Electronic Cited Medium: Internet ISSN: 1879-0852 (Electronic) Linking ISSN: 09598049 NLM ISO Abbreviation: Eur J Cancer Subsets: MEDLINE
Database: MEDLINE Ultimate
Description
ISSN:1879-0852
DOI:10.1016/j.ejca.2025.115470